A phase I study of concurrent 9-nitro-20(s)-camptothecin (9NC/Orathecin) and radiation therapy in the treatment of locally advanced adenocarcinoma of the pancreas

Radiotherapy and Oncology

Volumn 76, Issue 1, 2005, Pages 54-58

  Tedesco, Karen L ^a   Berlin, Jordan ^a   Rothenberg, Mace ^a   Choy, Hak ^a   Wyman, Ken ^a   Pearson, Adrian Scott ^b   Beauchamp, Robert Daniel ^b   Merchant, Nipun ^b   Lockhart, A Craig ^a   Shyr, Yu ^a,c   Caillouette, Carol ^a   Chakravarthy, Bapsi ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c SuperGen Inc   (United States)

Author keywords

Chemoradiation; Topoisomerase I inhibitors; Unresectable

Indexed keywords

RUBITECAN;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DEHYDRATION; FATIGUE; FEMALE; HUMAN; MALE; MAXIMUM TOLERATED DOSE; MULTIMODALITY CANCER THERAPY; MUSCLE WEAKNESS; NAUSEA; PANCREAS ADENOCARCINOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; VOMITING;

ADENOCARCINOMA; ADMINISTRATION, ORAL; AGED; CAMPTOTHECIN; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY; RADIOTHERAPY DOSAGE;

EID: 23244443466     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2005.04.005     Document Type: Article

References (27)

1. Gastrointestinal Tumor Study Group Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone J Natl Cancer Inst 80 1988 751 755
2. G.P. Amorino, S.K. Hercules, P.J. Mohr, H. Pyo, and H. Choy Preclinical evaluation of the orally active camptothecin analog, RFS-2000 (9-nitro-20(S)-camptothecin) as a radiation enhancer Int J Radiat Oncol Biol Phys 47 2000 503 509
3. A.W. Blackstock, F. Richards, D. White, and G. Lesser Twice-weekly gemcitabine and concurrent thoracic radiation for advanced non small-cell lung cancer Clin Lung Cancer 1 1999 153 154
4. D.A. Boothman, M. Wang, and R.A. Schea Posttreatment exposure to camptothecin enhances the lethal effects of X-rays on radioresistant human malignant melanoma cells Int J Radiat Oncol Biol Phys 24 1992 939 948
5. H.A. Burris III, S. Rivkin, and R. Reynolds Phase II trial of oral rubitecan in previously treated pancreatic cancer patients Oncologist 10 2005 183 190
6. A.Y. Chen, and L.F. Liu Design of topoisomerase inhibitors to overcome MDR1-mediated drug resistance Adv Pharmacol 29B 1994 245 256
7. H.R. Hinz, N.J. Harris, E.A. Natelson, and B.C. Giovanella Pharmacokinetics of the in vivo and in vitro conversion of 9-nitro-20(S)- camptothecin to 9-amino-20(S)-camptothecin in humans, dogs, and mice Cancer Res 54 1994 3096 3100
8. C. Jaxel, K.W. Kohn, M.C. Wani, M.E. Wall, and Y. Pommier Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity Cancer Res 49 1989 1465 1469
9. A. Jemal, T. Murray, and E. Ward Cancer statistics CA Cancer J Clin 55 2005 10 30
10. K.R. Kemp, J.G. Liehr, and B. Giovanella Combined radiation and 9-nitrocamptothecin (rubitecan) in the treatment of locally advanced pancreatic cancer Ann NY Acad Sci 922 2000 320 323
11. J-S. Kim, G.P. Amorino, H. Pyo, Q. Cao, and H. Choy Radiation enhancement by the combined use of topoisomerase I inhibitors, RFS-2000 or CPT-11, and topoisomerase II inhibitor etoposide in human lung cancer cells Radiother Oncol 62 2002 61 67
12. A.V. Kirichenko, T.A. Rich, R.A. Newman, and E.L. Travis Potentiation of murine MCa-4 carcinoma radioresponse by 9-amino-20(S)-camptothecin Cancer Res 57 1997 1929 1933
13. M.M. Konstadoulakis, P.T. Antonakis, and B.G. Tsibloulis A phase II study of 9-nitrocamptothecin in patients with advanced pancreatic adenocarcinoma Cancer Chemother Pharmacol 48 2001 417 420
14. J.P. Lamond, M. Wang, T.J. Kinsella, and D.A. Boothman Radiation lethality enhancement with 9-aminocamptothecin: comparison to other topoisomerase I inhibitors Int J Radiat Oncol Biol Phys 36 1996 369 376
15. J.A. Martenson, A.P. Vigliotti, and H.C. Pitot A phase I study of radiation therapy and twice-weekly gemcitabine and cisplatin in patients with locally advanced pancreatic cancer Int J Radiat Oncol Biol Phys 55 2003 1305 1310
16. A.B. Miller, B. Hoogstraten, M. Staquet, and A. Winkler Reporting results of cancer treatment Cancer 47 1981 207 214
17. C.G. Moertel, S. Frytak, R.G. Hahn, and The Gastrointestinal Tumor Study Group Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads+5-fluorouracil), and high dose radiation +5-fluorouracil Cancer 48 1981 1705 1710
18. E.A. Natelson, B.C. Giovanella, and C.F. Verschraegen Phase I clinical and pharmacological studies of 20-(S)-camptothecin and 20-(S)-9- nitrocamptothecin as anticancer agents Ann NY Acad Sci 803 1996 224 230
19. NCI/CTC. http://ctep.info.nih.gov.
20. P. Pantazis, D. Chatterjee, Z. Han, and J. Wyche Differentiation of human malignant melanoma cells that escape apoptosis after treatment with 9-nitrocamptothecin in vitro Neoplasia 1 1999 231 240
21. P. Pantazis, J.A. Early, and A.J. Kozielski Regression of human breast carcinoma tumors in immunodeficient mice treated with 9-nitrocamptothecin: differential response of nontumorigenic and tumorigenic human breast cells in vitro Cancer Res 53 1993 1577 1582
22. P. Pantazis, H.R. Hinz, and J.T. Mendoza Complete inhibition of growth followed by death of human malignant melanoma cells in vitro and regression of human melanoma xenografts in immunodeficient mice induced by camptothecins Cancer Res 52 1992 3980 3987
23. P. Pantazis, A.J. Kozielski, and J.T. Mendoza Camptothecin derivatives induce regression of human ovarian carcinomas grown in nude mice and distinguish between non-tumorigenic and tumorigenic cells in vitro Int J Cancer 53 1993 863 871
24. J.M. Pipas, S.E. Mitchell, and R.J. Barth Jr Phase I study of twice-weekly gemcitabine and concomitant external-beam radiotherapy in patients with adenocarcinoma of the pancreas Int J Radiat Oncol Biol Phys 50 2001 1317 1322
25. J.S. Stehlin, B.C. Giovanella, and E.A. Natelson A study of 9-nitrocamptothecin (RFS-2000) in patients with advanced pancreatic cancer Int J Oncol 14 1999 821 831
26. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
27. C.F. Verschraegen, E.A. Natelson, and B.C. Giovanella A phase I clinical and pharmacological study of oral 9-nitrocamptothecin, a novel water-insoluble topoisomerase I inhibitor Anti-Cancer Drugs 9 1998 36 44